Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press3210.17650/2313-805X.2015.2.2.56-62RESEARCH ARTICLESЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИDiagnostic significance of DNA and antibodies against capsid antigens of anti-Epstein–Barr virus antibodies levels in blood plasma of nasopharyngeal carcinoma patients from non-endemic regionДиагностическая значимость уровней ДНК и антител к капсидному антигену вируса Эпштейна–Барр в плазме крови больных раком носоглотки в неэндемическом регионеGurtsevichV. E.ГурцевичВладимир Эдуардович
Russian Federation

Research Institute of Carcinogenesis, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Россия, 115478, Москва, Каширское шоссе, 24

gurvlad532@yahoo.comSenyutaN. B.СенютаН. Б.
Russian Federation

Research Institute of Carcinogenesis, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Россия, 115478, Москва, Каширское шоссе, 24

KondratovaV. N.КондратоваВ. Н.
Russian Federation

Research Institute of Carcinogenesis, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Россия, 115478, Москва, Каширское шоссе, 24

GoncharovaE. V.ГончароваЕ. В.
Russian Federation

Research Institute of Clinical Oncology, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Научно-исследовательский институт клинической онкологии, Россия, 115478, Москва, Каширское шоссе, 23

IgnatovaA. V.ИгнатоваА. В.
Russian Federation

Research Institute of Clinical Oncology, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Научно-исследовательский институт клинической онкологии, Россия, 115478, Москва, Каширское шоссе, 23

LomayaM. V.ЛомаяМ. В.
Russian Federation

Research Institute of Clinical Oncology, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Научно-исследовательский институт клинической онкологии, Россия, 115478, Москва, Каширское шоссе, 23

KropotovM. A.КропотовМ. А.
Russian Federation

Research Institute of Clinical Oncology, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Научно-исследовательский институт клинической онкологии, Россия, 115478, Москва, Каширское шоссе, 23

MudunovA. M.МудуновА. М.
Russian Federation

Research Institute of Clinical Oncology, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Научно-исследовательский институт клинической онкологии, Россия, 115478, Москва, Каширское шоссе, 23

LichtensteinA. V.ЛихтенштейнА. В.
Russian Federation

Research Institute of Carcinogenesis, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Россия, 115478, Москва, Каширское шоссе, 24

N. N. Blokhin Russian Cancer Research CenterНИИ канцерогенеза ФГБНУ «РОНЦ им. Н. Н. Блохина»N. N. Blokhin Russian Cancer Research CenterФГБНУ «РОНЦ им. Н. Н. Блохина»150520152256620306201503062015Copyright ©; 2015, Gurtsevich V.E., Senyuta N.B., Kondratova V.N., Goncharova E.V., Ignatova A.V., Lomaya M.V., Kropotov M.A., Mudunov A.M., Lichtenstein A.V.Copyright ©; 2015, Гурцевич В.Э., Сенюта Н.Б., Кондратова В.Н., Гончарова Е.В., Игнатова А.В., Ломая М.В., Кропотов М.А., Мудунов А.М., Лихтенштейн А.В.2015Gurtsevich V.E., Senyuta N.B., Kondratova V.N., Goncharova E.V., Ignatova A.V., Lomaya M.V., Kropotov M.A., Mudunov A.M., Lichtenstein A.V.Гурцевич В.Э., Сенюта Н.Б., Кондратова В.Н., Гончарова Е.В., Игнатова А.В., Ломая М.В., Кропотов М.А., Мудунов А.М., Лихтенштейн А.В.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/32

Epstein–Barr virus (EBV), a representative of the herpesvirus family, is the etiological agent for a number of benign and malignant human neoplasms. Among the latter, the nasopharyngeal carcinoma (NPC) occupies a special place. In NPC development EBV plays a key role stimulating the progression of the pathological process from precancerous lesions to the cancer development. For most NPC patients, elevated levels of humoral IgG and IgA antibodies against capsid and early EBV antigens are characteristic and their antibody titers rise to high levels long before the diagnosis of cancer. Using this phenomenon, virus-specific antibodies are used for many years as markers for NPC screening, especially in cases of undiagnosed primary lesion. In recent years, in endemic for NPC regions (South China, South-East Asia) a great attention has been paid to the use of quantitative determination of EBV DNA copies in the blood plasma of patients with NPC as a method of early cancer detection and monitoring.

The aim of this study was to compare clinical significance of EBV DNA and humoral antibodies levels in blood plasma of NPC patients in non-endemic region, Russia. The results obtained indicate that both markers DNA / EBV and IgA antibodies against capsid EBV antigens can be successfully used for diagnosis of NPC in non-endemic region. However, in comparison with the virus-specific antibody titers, the viral DNA levels in the patients plasma are more sensitive and specific as NPC marker reflecting the efficacy of the therapy, and the state of remission or relapse.

nasopharyngeal carcinomaEpstein–Barr viruscapsid antigenearly antigenIgG- and IgA-antibody titersremissionrelapse or stabilization of the tumor processEpstein–Barr virus DNA concentration in 1 ml of blood plasmanasopharyngeal carcinomaрак носоглоткивирус Эпштейна–Барркапсидный антигенранний антигентитры IgG- и IgA-антителремис- сиярецидивстабилизация опухолевого процессаконцентрация ДНК вируса Эпштейна–Барр в 1 мл плазмы кровидиагностика рака носоглотки1. Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757–68.Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757–68.2. Gu A.D., Zeng M.S., Qian C.N. The criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiation. Int J Mol Sci 2012;13(10):13737–47.Gu A.D., Zeng M.S., Qian C.N. The criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiation. Int J Mol Sci 2012;13(10):13737–47.3. Chang C.M., Yu K.J., Mbulaiteye S.M. et al. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res 2009;143(2):209–21.Chang C.M., Yu K.J., Mbulaiteye S.M. et al. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res 2009;143(2):209–21.4. Yu M.C., Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002;12(6):421–9.Yu M.C., Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002;12(6):421–9.5. Licitra L., Bernier J., Cvitkovic E. et al. Cancer of the nasopharynx. Crit Rev Oncol Hematol 2003;45(2):199–213.Licitra L., Bernier J., Cvitkovic E. et al. Cancer of the nasopharynx. Crit Rev Oncol Hematol 2003;45(2):199–213.6. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ. Вестник РОНЦ им. Н.Н. Блохина РАМН 2008;19(2 прил. 1). [Davydov M.I., Axel E.M. Statistics of malignant neoplasms in Russia and CIS Countries. Vestnik RONC im. N.N. Blokhina RAMN = Herald of the N.N. Blokhin Russian Cancer Research Center with the RAMS 2008;19(2 Suppl 1). (In Russ.)].Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ. Вестник РОНЦ им. Н.Н. Блохина РАМН 2008;19(2 прил. 1). [Davydov M.I., Axel E.M. Statistics of malignant neoplasms in Russia and CIS Countries. Vestnik RONC im. N.N. Blokhina RAMN = Herald of the N.N. Blokhin Russian Cancer Research Center with the RAMS 2008;19(2 Suppl 1). (In Russ.)].7. Barnes L., Eveson J.W., Reichart P., Sidransky D. Pathology and genetics of head and neck tumors. Lyon: IARC Press, 2005.Barnes L., Eveson J.W., Reichart P., Sidransky D. Pathology and genetics of head and neck tumors. Lyon: IARC Press, 2005.8. Luo S., Zhao L., Wang J. et al. Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China. Head Neck 2014;36(6):841–7.Luo S., Zhao L., Wang J. et al. Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China. Head Neck 2014;36(6):841–7.9. Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis 2006;1:23.Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis 2006;1:23.10. Cho W.C. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007;6:1.Cho W.C. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007;6:1.11. Hubert A., De-The G. Dietary behavior, way of life, and nasopharyngeal cancer. Bull Cancer 1982;69(5):476–82.Hubert A., De-The G. Dietary behavior, way of life, and nasopharyngeal cancer. Bull Cancer 1982;69(5):476–82.12. Li J., Qian C.N., Zeng Y.X. Regulatory T cells and EBV associated malignancies. Int Immunopharmacol 2009;9(5):590–2.Li J., Qian C.N., Zeng Y.X. Regulatory T cells and EBV associated malignancies. Int Immunopharmacol 2009;9(5):590–2.13. Li X., Fasano R., Wang E. et al. HLA associations with nasopharyngeal carcinoma. Curr Mol Med 2009;9(6):751–65.Li X., Fasano R., Wang E. et al. HLA associations with nasopharyngeal carcinoma. Curr Mol Med 2009;9(6):751–65.14. Yeung W.M., Zong Y.S., Chiu C.T. et al. Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ. Int J Cancer 1993;53(5):746–50.Yeung W.M., Zong Y.S., Chiu C.T. et al. Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ. Int J Cancer 1993;53(5):746–50.15. Gurtsevitch V., Ruiz R., Stepina V. et al. Epstein-Barr viral serology in nasopharyngeal carcinoma patients in the USSR and Cuba, and its value for differential diagnosis of the disease. Int J Cancer 1986;37(3): 375–81.Gurtsevitch V., Ruiz R., Stepina V. et al. Epstein-Barr viral serology in nasopharyngeal carcinoma patients in the USSR and Cuba, and its value for differential diagnosis of the disease. Int J Cancer 1986;37(3): 375–81.16. Pearson G.R. Epstein-Barr virus and nasopharyngeal carcinoma. J Cell Biochem Suppl 1993;17F:150–4.Pearson G.R. Epstein-Barr virus and nasopharyngeal carcinoma. J Cell Biochem Suppl 1993;17F:150–4.17. Ho H.C., Ng M.H., Kwan H.C. Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma. Br J Cancer 1978;37(3):356–62.Ho H.C., Ng M.H., Kwan H.C. Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma. Br J Cancer 1978;37(3):356–62.18. Song C., Yang S. A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of nasopharyngeal carcinoma. Pak J Med Sci 2013;29(3):885–90.Song C., Yang S. A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of nasopharyngeal carcinoma. Pak J Med Sci 2013;29(3):885–90.19. Lichtenstein A.V., Melkonyan H.S., Tomei L.D., Umansky S.R. Circulating nucleic acids and apoptosis. Ann NY Acad Sci 2001;945:239–49.Lichtenstein A.V., Melkonyan H.S., Tomei L.D., Umansky S.R. Circulating nucleic acids and apoptosis. Ann NY Acad Sci 2001;945:239–49.20. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2(3):210–9.Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2(3):210–9.21. Skvortsova T.E., Rykova E.Y., Tamkovich S.N. et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer 2006;94(10):1492–5.Skvortsova T.E., Rykova E.Y., Tamkovich S.N. et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer 2006;94(10):1492–5.22. Lo Y.M., Chan L.Y., Chan A.T. et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999;59(21): 5452–5.Lo Y.M., Chan L.Y., Chan A.T. et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999;59(21): 5452–5.23. Hou X., Zhao C., Guo Y. et al. Different Clinical significance of pre- and posttreatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol (R Coll Radiol) 2011; 23(2):128–33.Hou X., Zhao C., Guo Y. et al. Different Clinical significance of pre- and posttreatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol (R Coll Radiol) 2011; 23(2):128–33.24. Wang W.Y., Twu C.W., Chen H.H. et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010;16(3):1016–24.Wang W.Y., Twu C.W., Chen H.H. et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010;16(3):1016–24.25. Kondratova V.N., Botezatu I.V., Shelepov V.P., Lichtenstein A.V. Tube gel isotachophoresis: a method for quantitative isolation of nucleic acids from diluted solutions. Anal Biochem 2011;408(2):304–8.Kondratova V.N., Botezatu I.V., Shelepov V.P., Lichtenstein A.V. Tube gel isotachophoresis: a method for quantitative isolation of nucleic acids from diluted solutions. Anal Biochem 2011;408(2):304–8.26. Lawrence J.B., Villnave C.A., Singer R.H. Sensitive, high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line. Cell 1988;52(1): 51–61.Lawrence J.B., Villnave C.A., Singer R.H. Sensitive, high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line. Cell 1988;52(1): 51–61.27. Botezatu I.V., Kondratova V.N., Shelepov V.P., Lichtenstein A.V. DNA melting analysis: application of the "open tube" format for detection of mutant KRAS. Anal Biochem 2011;419(2):302–8.Botezatu I.V., Kondratova V.N., Shelepov V.P., Lichtenstein A.V. DNA melting analysis: application of the "open tube" format for detection of mutant KRAS. Anal Biochem 2011;419(2):302–8.28. Гурцевич В.Э., Степина В.Н., Сенюта Н.Б. и др. Гуморальный иммунный ответ к вирусу Эпштейна–Барр в диагностике рака носоглотки (обзор литературы и 30-летний опыт собственных исследований). Вестник РОНЦ им. Н.Н. Блохина РАМН 2011;22(2):20–30. [Gurtsevich V.E., Stepina V.N., Senyuta N.B. et al. Humoral immune response to Epstein–Barr virus in diagnostics of nasopharyngeal carcinoma (review of references and 30-year experience of own studies). Vestnik RONC im. N.N. Blokhina RAMN = Herald of the N.N. Blokhin Russian Cancer Research Center with the RAMS 2011;22(2): 20–30. (In Russ.)].Гурцевич В.Э., Степина В.Н., Сенюта Н.Б. и др. Гуморальный иммунный ответ к вирусу Эпштейна–Барр в диагностике рака носоглотки (обзор литературы и 30-летний опыт собственных исследований). Вестник РОНЦ им. Н.Н. Блохина РАМН 2011;22(2):20–30. [Gurtsevich V.E., Stepina V.N., Senyuta N.B. et al. Humoral immune response to Epstein–Barr virus in diagnostics of nasopharyngeal carcinoma (review of references and 30-year experience of own studies). Vestnik RONC im. N.N. Blokhina RAMN = Herald of the N.N. Blokhin Russian Cancer Research Center with the RAMS 2011;22(2): 20–30. (In Russ.)].29. Leung S.F., Chan K.C., Ma B.B. et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 2014; 25(6):1204–8.Leung S.F., Chan K.C., Ma B.B. et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 2014; 25(6):1204–8.